ArticleCancer immunology, immunotherapy : CII2006
Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
Article in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Intrinsically de-sialylated CD103(+) CD8 T cells mediate beneficial anti-glioma immune responses.Cancer immunology, immunotherapy : CII · 2014Trial
- Exploring dendritic cell subtypes in cancer immunotherapy: unraveling the role of mature regulatory dendritic cells.Upsala journal of medical sciences · 2024Review
- Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.Oncogene · 2023Article
- Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination.Frontiers in oncology · 2022Article
- Myeloid and plasmacytoid dendritic cell combined vaccines loaded with heat-treated tumor cell lysates enhance antitumor activity in murine lung cancer.Oncology letters · 2021Article
- Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.Frontiers in immunology · 2021Review
- Review
- A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine.Oncology letters · 2018Article
- CD103Oncology research · 2018Article
- Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.Scientific reports · 2017Article
- Vaccine-based immunotherapeutic approaches to gliomas and beyond.Nature reviews. Neurology · 2017Review
- Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.BMC cancer · 2016Article
- Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.Journal of experimental & clinical cancer research : CR · 2016Article
- Overview of current immunotherapeutic strategies for glioma.Immunotherapy · 2015Review
- Brain Tumor Immunotherapy: What have We Learned so Far?Frontiers in oncology · 2015Review
- The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma.PloS one · 2012Article
- Intracranial implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas.Journal of visualized experiments : JoVE · 2011Article
- The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma.Nutrition & metabolism · 2010Article
- Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.Journal of neuro-oncology · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of malignant gliomas remains dismal and alternative therapeutic strategies are required. Immunotherapy with dendritic cells (DCs) pulsed with tumour antigens emerges as a promising approach. Many parameters influence the efficacy of DC-based vaccines and need to be optimised in preclinical models. The present study compares different vaccine schedules using DCs loaded with tumour cell lysate (DC-Lysate) for increasing long-term survival in the GL26 orthotopic murine glioma model, focusing on the number of injections and an optimal way to recall antitumour immune response. Double vaccination with DC-Lysate strongly prolonged median survival compared to unvaccinated animals (mean survival 87.5 days vs. 25 days; p < 0.0001). In vitro data showed specific cytotoxic activity against GL26. However, late tumour relapses frequently occurred after 3 months and only 20% of mice were finally cured at 7 months. While one, two or three DC injections gave identical survival, a boost using only tumour lysate after initial DC-Lysate priming dramatically improved long-term survival in vaccinated mice, compared to the double DC-Lysate group, with 67.5% of animals cured at 7 months (p < 0.0001). In vitro data showed better specific CTL response and also the induction of specific anti-GL26 antibodies in the DC-Lysate/Lysate group, which mediated Complement Dependent Cytotoxicity. These experimental data may be of importance for the design of clinical trials that currently use multiple DC injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.